Drug stocks give FTSE a shot in the arm

clock •

The FTSE 100 is off to a good start to the week with gains of 12.5 points, or 0.23%, to 5,544.1, with drug stocks leading the advance in response to news a US judge has upheld key patents on Pfizer's Lipitor cholesterol drug.

AstraZeneca, which makes the Crestor cholesterol treatment, has risen 65p, or 2.37%, to 2,812p, while GlaxoSmithKline has gained 30p, or 2.05%, to 1,490p, as the US ruling handed Pfizer patent protection on the world's best-selling drug until June 2011, dealing a blow to generic drug makers. Elsewhere, Kazakhstan miner Kazakhmys, entering the FTSE 100 for the first time since its October flotation, has fallen 8p, or 1.16%, to 680p, after it said copper cathode production in the first nine months of the year was in line with expectations. Housebuilder Persimmon, which is also making it...

To continue reading this article...

Join Professional Adviser for free

  • Unlimited access to real-time news, industry insights and market intelligence
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection
  • Members-only access to the editor’s weekly Friday commentary
  • Be the first to hear about our events and awards programmes

Join

 

Already a Professional Adviser member?

Login

More on Investment

Why managing retirement risk matters more than predicting markets

Why managing retirement risk matters more than predicting markets

'Helping clients understand, prepare for and navigate uncertainty'

Andy Brown
clock 12 November 2026 • 4 min read
Solving private markets risks 'almost mission impossible'

Solving private markets risks 'almost mission impossible'

Julius Baer’s Cyril Demaria-Bengochea speaks to Professional Adviser

Sophia Panayi
clock 12 November 2026 • 3 min read
Anthropic bankers preparing to increase IPO valuation to $1.5trn – reports

Anthropic bankers preparing to increase IPO valuation to $1.5trn – reports

Draft prospectus filed on Tuesday

Jack Roach
clock 11 November 2026 • 2 min read